Vice President and Equity Research Analyst at Piper Sandler
Jungyu Ong is a Vice President and Equity Research Analyst at Piper Sandler, specializing in biotechnology sector research with a primary focus on small- and mid-cap biotech companies. He covers a portfolio of companies including Argenx, Ascendis Pharma, and Apellis Pharmaceuticals, and his recommendations have led to a success rate of approximately 54%, with an average return per rating of about 12% as tracked by TipRanks. Ong began his career in equity research at Piper Sandler and has steadily advanced within the firm since joining in 2020, bringing a background in biomedical research and data analytics to his analysis. He holds key industry credentials, including FINRA Series 7, 63, 86, and 87 securities licenses, and is recognized for his detailed, science-driven investment insights in the healthcare sector.
Asked about the rationale for the new mini-tablet formulation, whether a bridging study was needed, and for more detail on potential strategic opportunities.
The new formulation improves dosing accuracy and administration flexibility; a required bridging study is complete. The company is exploring a wide range of strategic opportunities with global and regional players but cannot be more specific.